Skip to main content
Clinical Trials/NCT00872833
NCT00872833CompletedNot Applicable

Assessment of Pain in Transfusion Dependent Patients With Thalassemia During Transfusion Cycles

Carelon Research9 sites in 2 countries32 target enrollmentStarted: July 2009Last updated:
Conditions

Trial Snapshot

Phase
Not Applicable
Status
Completed
Sponsor
Enrollment
32
Locations
9
Primary Endpoint
Report of Pain by Age Group

Study Overview

Brief Summary

Thalassemia is an inherited blood disorder that can result in mild to severe anemia. Regular blood transfusions, which refresh the healthy red blood cell supply, are one treatment for thalassemia. People with thalassemia often experience pain, but the exact source of pain remains unknown. This study will examine how pain varies during the blood transfusion cycle in people with thalassemia who are treated with regular blood transfusions.

Detailed Description

Thalassemia is an inherited blood disorder in which the body makes an abnormal form of hemoglobin-the protein in red blood cells that carries oxygen. People with thalassemia often experience fatigue, shortness of breath, and pain. There have been no previous research studies that have fully examined pain levels in people with thalassemia, and as a result, the sources of pain remain unknown. This study is a substudy of the Assessment of Pain study, which is a Thalassemia Clinical Research Network (TCRN) study that is examining the prevalence and severity of pain in people with transfusion-dependent thalassemia and non-transfusion-dependant thalassemia. This study will enroll a subset of participants from the Assessment of Pain study who have transfusion-dependant thalassemia. The purpose of this study is to examine whether pain varies during the blood transfusion cycle and whether the length of the transfusion cycle affects pain levels in people with transfusion-dependent thalassemia.

Participants will complete daily questionnaires through an automated telephone system to assess pain levels during three blood transfusion cycles. Each transfusion cycle will last between 2 to 4 weeks, depending on the individual needs of the participant, and the cycles will be separated by at least 3 months but no more than 4 months. Prior to each transfusion cycle, study researchers will review participants' medical records for certain blood level measurements.

Study Design

Study Type
Observational
Observational Model
Cohort
Time Perspective
Prospective

Eligibility Criteria

Ages
18 Years to — (Adult, Older Adult)
Sex
All
Accepts Healthy Volunteers
No

Inclusion Criteria

  • Participating in the Thalassemia Clinical Research Network Assessment of Pain study
  • Has a transfusion dependence of at least eight transfusions per year
  • Diagnosis of beta thalassemia or E-beta-thalassemia
  • Experiences at least "mild" pain in the 1 month before study entry, as measured by the response to the Brief Pain Inventory (BPI) question #6 from the Assessment of Pain study

Exclusion Criteria

  • Unwillingness or inability to complete the Brief Pain Inventory Short Form (BPI-SF) on a daily basis

Outcomes

Primary Outcomes

Report of Pain by Age Group

Time Frame: measured daily over the 3 transfusion cycles

Subjects reported whether or not they had pain (yes/no) during each transfusion cycle (data on up to 3 transfusion cycles were collected for each subject). The percent of subject-cycles with pain was calculated for the quartiles of the transfusion cycle.

Secondary Outcomes

  • Report of Pain by Length of the Transfusion Cycle(measured daily over the 3 transfusion cycles)

Investigators

Sponsor
Carelon Research
Sponsor Class
Other
Responsible Party
Sponsor

Study Sites (9)

Loading locations...

Similar Trials